NCT03226704 2026-03-05
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
National Institutes of Health Clinical Center (CC)
Enrolling by invitation
Clinical Trials
7 trialsNCT07348575 2026-01-16
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
Second Affiliated Hospital of Nanchang University
Phase 3 Enrolling by invitation
NCT07168486 2025-09-11
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Phase 1 Enrolling by invitation
NCT06827782 2025-08-15
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Enrolling by invitation
NCT04488354 2025-01-10
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
Phase 1 Enrolling by invitation
NCT05690191 2023-01-19
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Second Affiliated Hospital of Soochow University
Enrolling by invitation
NCT04491721 2020-07-29
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
ChineseAMS
Enrolling by invitation